Preventive effect of postoperative TACE against small hepatocellular carcinoma recurrence

Clinical RCT of preventive effect of adjuvant TACE against small hepatocellular carcinoma recurrence after liver resection

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000300

Enrollment

Unknown

Registered

2008-11-20

Start date

2008-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatocelullar carcinoma

Interventions

control group:All patients will accept neither TACE nor other chemotherapy and radiotherapy one month after liver resection.

TACE group:All patients will be performed TACE (lipiodol 5ml, epirubicin 20mg, 5FU 500mg, hydroxy camptothecin 10mg)one month after liver resection.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. HCC; 2. Tumor is solitary and <=5cm in diameter; 3. Patient's liver function (Child A) and general condition can afford the radical hepatectomy; 4. Patient's liver function should be better than Child B in one month after liver resection; 4. No intra-hepatic recurrence and extra-hepatic metastasis.

Exclusion criteria

Exclusion criteria: 1. Multiple tumour and the size >5cm in diameter; 2. Patient's liver function (Child B or C) and general condition can not afford the radical hepatectomy; 3. Patient's liver function is Child C in one month after liver resection; 4. Intra-hepatic recurrence and extra-hepatic metastasis exist.

Design outcomes

Primary

Measure	Time frame
disease free survival time;	—

Secondary

Measure	Time frame
overall suvival time;	—

Countries

China

Contacts

Public ContactXu Feng

victorf2255@hotmail.com+86 021 25070773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026